# A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 and 24 Months Old

> **NCT07477132** · PHASE4 · NOT_YET_RECRUITING · sponsor: **University Hospital, Caen** · enrollment: 99 (estimated)

## Conditions studied

- Curarization, Postoperative Residual

## Interventions

- **DRUG:** Sugammadex

## Key facts

- **NCT ID:** NCT07477132
- **Lead sponsor:** University Hospital, Caen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-30
- **Primary completion:** 2027-08-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 99 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07477132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07477132, "A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 and 24 Months Old". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07477132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*